Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

APPROVED_FOR_MARKETING

Conditions studied: COVID19

In brief

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Key facts

Study ID
NCT04338360
Run by
Mayo Clinic
Last updated by the study team
2020-09-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.